Sensorion Senior Management to Attend Four Conferences in April 2021 - Business Wire

Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL).

www.sensorion.comLabel: SENSORIONISIN: FR0012596468Mnemonic: ALSENDisclaimerThis press release contains certain forward-looking statements concerning Sensorion and its business.

The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion.

The communication of this press release in certain countries may constitute a violation of local laws and regulations.

Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

Published On: Wed, 31 Mar 2021 06:30:00 GMT